Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warns of unapproved H1N1 products

This article was originally published in The Tan Sheet

Executive Summary

FDA warns Tib Molbiol in an Aug. 24 letter that its LightMax InfA swine H1 kit to test for swine flu is unapproved and unauthorized for sale. In a warning sent by e-mail to the online firm, the agency requests Tib Molbiol "immediately cease marketing" the kit and within 48 hours of receiving the warning letter inform FDA how it will address the violations. The agency added the test product to a list of 131 other "fraudulent products" that "illegally" market unapproved or unauthorized products related to the 2009 H1N1 flu at

You may also be interested in...

FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

A warning letter sent jointly by FDA and the Federal Trade Commission takes a double-pronged approach toward cracking down on a supplement marketer's claims regarding the H1N1 flu virus

Hand Sanitizers Limited To Sterile Claims But Cleaning Up Amid Flu Worries

Consumer fears stemming from a second wave of 2009-H1N1 flu virus cases are helping drive sales of hand sanitizers, but marketers must tread lightly when it comes to associating their products with protection against viruses

QUOTED. 19 April 2021. Jeff Shuren & William Maisel

Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts